glycine has been researched along with Depressive Disorder, Major in 13 studies
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " MDD patients had significantly higher serum levels of glutamic acid, aspartic acid and glycine but lower levels of 3-Hydroxykynurenine; glutamic acid and phenylalanine levels also correlated with depression severity." | 4.31 | The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity. ( Ching, J; Ho, CSH; Tay, GWN; Wee, HN, 2023) |
| " Based on the POC study described here, a multiple dose study has been completed which showed sustained therapeutic benefit with repeated dosing of GLYX-13 for more than 6 weeks." | 2.80 | Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. ( Burch, RM; Macaluso, M; Mehra, DO; Moskal, JR; Preskorn, S; Zammit, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, CSH | 1 |
| Tay, GWN | 1 |
| Wee, HN | 1 |
| Ching, J | 1 |
| Lu, YR | 2 |
| Fu, XY | 2 |
| Shi, LG | 1 |
| Jiang, Y | 1 |
| Wu, JL | 2 |
| Weng, XJ | 1 |
| Wang, ZP | 1 |
| Wu, XY | 2 |
| Lin, Z | 1 |
| Liu, WB | 1 |
| Li, HC | 1 |
| Luo, JH | 1 |
| Bao, AM | 2 |
| Preskorn, S | 1 |
| Macaluso, M | 1 |
| Mehra, DO | 1 |
| Zammit, G | 1 |
| Moskal, JR | 1 |
| Burch, RM | 1 |
| Zanos, P | 1 |
| Piantadosi, SC | 1 |
| Wu, HQ | 1 |
| Pribut, HJ | 1 |
| Dell, MJ | 1 |
| Can, A | 1 |
| Snodgrass, HR | 1 |
| Zarate, CA | 1 |
| Schwarcz, R | 1 |
| Gould, TD | 1 |
| Yohn, SE | 1 |
| Alberati, D | 1 |
| Correa, M | 1 |
| Salamone, JD | 1 |
| Ji, Y | 1 |
| Hebbring, S | 1 |
| Zhu, H | 1 |
| Jenkins, GD | 1 |
| Biernacka, J | 1 |
| Snyder, K | 1 |
| Drews, M | 1 |
| Fiehn, O | 1 |
| Zeng, Z | 1 |
| Schaid, D | 1 |
| Mrazek, DA | 1 |
| Kaddurah-Daouk, R | 1 |
| Weinshilboum, RM | 1 |
| Tunbridge, E | 1 |
| Burnet, PW | 1 |
| Sodhi, MS | 1 |
| Harrison, PJ | 1 |
| Sumiyoshi, T | 1 |
| Anil, AE | 1 |
| Jin, D | 1 |
| Jayathilake, K | 1 |
| Lee, M | 1 |
| Meltzer, HY | 1 |
| Yu, YW | 1 |
| Tsai, SJ | 1 |
| Liou, YJ | 1 |
| Hong, CJ | 1 |
| Chen, TJ | 1 |
| Frye, MA | 1 |
| Tsai, GE | 1 |
| Huggins, T | 1 |
| Coyle, JT | 1 |
| Post, RM | 1 |
| Oon, S | 1 |
| Yap, CH | 1 |
| Ihle, BU | 1 |
| Maes, M | 1 |
| Verkerk, R | 1 |
| Vandoolaeghe, E | 1 |
| Lin, A | 1 |
| Scharpé, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers[NCT01014650] | Phase 1 | 53 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder[NCT01234558] | Phase 2 | 115 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for glycine and Depressive Disorder, Major
| Article | Year |
|---|---|
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Discovery; Excit | 2015 |
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Discovery; Excit | 2015 |
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Discovery; Excit | 2015 |
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Discovery; Excit | 2015 |
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
Topics: Biomarkers, Pharmacological; Cell Line; Chromosomes, Human, Pair 9; Citalopram; Depressive Disorder, | 2011 |
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Female; Glycine; Humans; Ma | 2004 |
Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders.
Topics: Adult; Asian People; Asparagine; Depressive Disorder, Major; Female; Fluoxetine; Glycine; Humans; Li | 2006 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
8 other studies available for glycine and Depressive Disorder, Major
| Article | Year |
|---|---|
The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity.
Topics: Amino Acids; Aspartic Acid; Biomarkers; Depression; Depressive Disorder, Major; Glutamic Acid; Glyci | 2023 |
Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder.
Topics: Adult; Aged; Amino Acids; Antidepressive Agents; Aspartic Acid; Biomarkers; Depressive Disorder, Maj | 2014 |
The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Depressive Disorder, Major; Glycine; Hindlim | 2015 |
Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.
Topics: Animals; Choice Behavior; Depressive Disorder, Major; Dopamine; Dopamine Antagonists; Dose-Response | 2017 |
[Alterations of plasma aspartic acid, glycine and asparagine levels in patients with major depressive disorder].
Topics: Adult; Aged; Antidepressive Agents; Asparagine; Aspartic Acid; Depressive Disorder, Major; Female; G | 2012 |
Catechol-o-methyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression.
Topics: Adult; Alanine; Analysis of Variance; Bipolar Disorder; Blotting, Southern; Case-Control Studies; Ca | 2004 |
Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Ch | 2007 |
Acute copper toxicity following copper glycinate injection.
Topics: Adult; Copper; Depressive Disorder, Major; Female; Glycine; Humans; Injections, Subcutaneous; Multip | 2006 |